Top Markets
#1 Siacoin Siacoin +32.74%
#2 Official Trump Official Trump +23.94%
#3 EXOD EXOD +22.08%
#4 Wrapped STX (Velar) Wrapped STX (Velar) +18.87%
#5 MowCat MowCat +17.75%
#6 Unit Pump Unit Pump +16.97%
#7 Pump.fun Pump.fun +16.97%
#8 Melania Meme Melania Meme +16.48%
#9 Siren Siren +15.35%
#10 Mubarak Mubarak +13.74%
Coin of the day
Siacoin Siacoin
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Annovis Bio, Inc. Annovis Bio, Inc.

Annovis Bio, Inc.

ANVS
Clasificación en acciones #23205
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on... Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
Precio por acción
$1.81
Última sincronización: 2026-08-21
Capitalización bursátil
$77.00M
Cambio (1 día)
1.30%
Cambio (1 año)
-23.63%
País
US
Comercio Annovis Bio, Inc. (ANVS)

Categoría

Healthcare
Ingresos de Annovis Bio, Inc. (ANVS)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Annovis Bio, Inc., los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Annovis Bio, Inc. desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH